Zacks Investment Research upgraded shares of BIOMIMETIC THER (BMTI) from NEUTRAL to OUTPERFORM on November 29, 2012, with a target price of $8.00.
BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) as its primary technology platform. This molecule is a synthetic copy of one of the body's principal agents to stimulate and direct healing and regeneration. The mechanism of action of this platform technology suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine. Additionally, BioMimetic Therapeutics has completed and ongoing clinical trials with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BIOMIMETIC THER (BMTI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment